Pharmasset Reports Financial Results for Quarter Ended Jun...($58229761 $75844399 ...),Health
Navigation Links
| HOME >> MEDICINE >> TECHNOLOGY |
Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
Date:8/14/2008
$58,229,761 $75,844,399
==========================
'/>"/>
| SOURCE Pharmasset, Inc. Copyright©2008 PR Newswire. All rights reserved |
Related medicine technology :
1. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
2. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
3. Pharmasset Receives Notice of Allowance
4. Pharmasset Nominates PSI-7851 as a Lead Development Candidate for the Treatment of Chronic Hepatitis C
5. Pharmasset Commences Dosing R7128 Cohorts 3 and 4 for the Treatment of Chronic Hepatitis C
6. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
8. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
9. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
10. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
11. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
Post Your Comments:
(Date:11/25/2008)... 25 CardioVascular,BioT...unced today that it has,dosed the first patient i...,clinical trial to treat patients with severe cor...the treatment of CORonary heart Disease) trial wil...controlled doses in approximately 120,patients wi...
(Date:11/24/2008)...., Nov. 24 Leaders of Sc...vided an update for investors on the company,s res... portfolio that includes 46 new entities in clinic...clinical studies. , , "Research and develop...ough as we continue our transformation," said Fred...
(Date:11/24/2008)...;D Update Today Unveils Rich Development Pipeline ... , KENILWORTH, N.J., Nov. 24 /PRNewswire-FirstC... today revealed top-line results of a long-term Ph...agent SAPHRIS(TM) (asenapine) demonstrating effica...ia. In this trial, asenapine was statistically si...
(Date:11/24/2008)...lo., Nov. 24 GeneThera, ...on begin offering its Real Time,PCR test for John...ory. , GeneThera is set to begin offering i...uary of 2009. According to GeneThera Chairman, Dr...g our real time PCR test for Johne,s disease,cal...
Breaking Medicine Technology:CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 2CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 2Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 2GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 3GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009. 4Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema 1440 1Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema 1440 2Its PUR 26 Simple 3A Save Money Improve Lives 12986 1Its PUR 26 Simple 3A Save Money Improve Lives 12986 2Its PUR 26 Simple 3A Save Money Improve Lives 12986 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 1US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 2US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 3US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 4US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 5US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 6US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 7US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 8US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 9US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 10US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 11US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 12US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 13US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 14US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 15US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 16US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 17US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 18US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 19US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 20US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 21US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 22US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 23US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 24US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 25US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results 3588 26Jackson Lewis to Support Presagias Integrated Absence 26 Disability Management Solution 12981 1Jackson Lewis to Support Presagias Integrated Absence 26 Disability Management Solution 12981 2[0] CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease[2] Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects[0] Schering-Plough Unveils Top-Line Study Results for SAPHRIS(TM) (asenapine) Demonstrating Efficacy in Long-Term Schizophrenia Relapse Prevention[1] GeneThera Announces it is Set to Begin Commercial Testing for Johne's Disease as Soon as January, 2009.
...8F) announces today,that it has received very posi... IIb/III clinical trial started in autumn 2006. BF... 5-aminolevulinic acid,(ALA) with the nanoemulsion...o placebo in the treatment of actinic keratosis. B...liminates tumor tissue,through a combination of an...
... Heart Journal , ,WINNIPEG, Manitoba - (July 11, ...ascular focused, biopharmaceutical company,today ...m the,STRATEGY (Single High-Dose Bolus Tirofiban a...re Metal Stent In Acute Myocardial,Infarction) stu...al,of the American College of Cardiology (JACC). ,...
Other Medicine Technology:Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy,of BF-200 ALA In Actinic Keratosis 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 2Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 3Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 4Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology 5(Date:12/1/2008)...lls shut down and stop dividing when their DNA is ..., so as to prevent damaged DNA from leading to unr...er, a new study, published in this week,s issue of...hut down they also spew proteins into their surrou...ts up conditions that support the development of a...
(Date:12/1/2008)...l Sadelain and colleagues, at Memorial Sloan-Kette... approach to modulate the expression of genes for ...ective anticancer therapy in mice. , Small, nonc...atural repressors of gene expression. In the study...pression of genes in immune cells known as T cells...
(Date:12/1/2008)..., Dec. 1 /PRNewswire-FirstCall/ - The Westaim Corp...cial meeting of shareholders of NUCRYST Pharmaceut...RYST shareholders of approximately US$15 million o...ew alternatives to maximize the value of its 74.5 ...ess Corporations Act, NUCRYST,s Board of Directors...
(Date:12/1/2008)...ELES, Dec. 1 Media entrepreneur, t...state investor and philanthropist John,Bendheim w...ors at their,annual "Road To A Cure" Gala, Decemb...tel. Rick Powell, Chairman of the Board of Govern...tz, Aaron Kaplan and Fran Solomon. The "Road To,...
Breaking Medicine News(10 mins):Health News:Escape cancer, but age sooner? The dark side of the tumor suppressing process 2Health News:The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders 2Health News:Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala 2[1] Escape cancer, but age sooner? The dark side of the tumor suppressing process[0] Harnessing miRNA natural gene repressors for anticancer therapy[0] The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders[0] Cedars-Sinai Board of Governors to Honor Ryan Seacrest & John Bendheim at Annual 'Road To A Cure' Gala
... the common cold remains as elusive as ever. A fed...the first drug aimed at treating the cause of the ...ed. In a unanimous decision, the Food and Drug Ad...l drugs said there were too many questions about t...
...hemists at the University of north Carolina at Ch... organisms convert genetic instructions into actio...unknown chemical site on a key enzyme that regulat...er known as RNA. When the chemical site is occupie...
...re right if they are feeling bombarded by commerci...ople instead of doctors tripled in the U.S. betwee...ertisements targeting consumers account for 15% of... up from almost 9% in 1996.// Spending that target...
...roup has petitioned the Food and Drug Administrati...Public Citizen says the drug, sold as Meridia, is ...diovascular causes such as heart attacks. But obes...ople died because of Meridia or because they were ...
Other Medicine News:Our electronic charts include a Patient Face Sheet, summarizing patient information and as many as six custom tabs, so you can customize which information is important for you to document. In additio
...mprises the core applications for health informati...onic medical record. The suite includes applicatio...ncy completion & release of information., Imp...nment, CHARMS 2000 modules leverage the most sophi...
Clinician's Desktop provides users the tools needed to coordinate information. Utilizing client/server technology Clinicians Desktop provides users with electronic medical records.
...le is a PDA medical software for patient tracking,...r Pocket PC PDA. With CPT codes and cross-linked I...ing, it will make your patient tracking, charge ca...ut-patient or in-patient environment. This PDA med...
Medicine Products:| Copyright © 2003-2008 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |